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1. Introduction  
The vasculitides include a broad spectrum of disorders that span a clinical spectrum from 
benign, self-limited disease to fulminant conditions that are fatal in the absence of therapy. 
Whereas the large-vessel vasculitides consist of 2 principal disorders, giant cell arteritis and 
Takayasu arteritis, the medium- and small-vessel vasculitides are much more diverse, 
including multiple diseases that can affect nearly every organ system (Seo & Stone, 2007). 
This article is the second of a 2-part series that focuses on the challenges faced by clinicians 
who care for patients with vasculitis. The first article in this series discussed the large-vessel 
vasculitides. The problem of systemic autoimmune diseases such as systemic vasculitis with 
vascular lesions of medium and small vessels, including: Wegener granulomatosis, Churg-
Strauss syndrome, microscopic poliangiitis, nodose poliarteriitis, attracts every year more 
attention of doctors, due to the worldwide relentless increase of patients with these diseases 
(Lhote & Guillevin, 2009; Tsukadaira, 2009). Recently, several reports have suggested that 
vasculitis is becoming more common. 
Systemic vasculitis is a group of heterogeneous diseases (syndromes), characterized by 
inflammation and damage to blood vessels and which compromises or destroys the vessel 
wall leading to haemorrhagic and ⁄ or ischaemic events, giving impetus to the development 
of a wide spectrum of symptoms and signs. The forms of vasculitis may be varied: primary 
[idiopathic, e.g. cutaneous leukocytoclastic angiitis, Wegener’s granulomatosis, Churg–
Strauss syndrome and microscopic polyangiitis ] and secondary [a manifestation of 
connective tissue disease, infection, adverse drug eruption, or a paraneoplastic 
phenomenon], local and generalized, transient, recurrent and chronic; included group of 
diseases in which vasculitis is a primary characteristic. They are general in nature, though 
sometimes a local clinic can manifest symptoms. General damage of blood vessels may 
occasionally appear and disappear, but in most cases there are long-term. Each new 
escalation leads to the increase of clinical symptoms. Clinical implications of SV course 
depend on a number of factors, including etiology, location, size and number of blood 
vessels, the extent and severity of disease, its activity and nature of treatment. 
Systemic vasculitis as the existing disease was first described by A. Cussmaul and I. Maier, 
when they reported a case of necrotizing arteritis and called it nodose periarteriitis. There 
are over twenty different forms of Systemic vasculitis. One of the first classification was 
their classification by P. Zeek's, which included five categories of Systemic vasculitis: nodose 
www.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 
 
256 
periarteriitis, hypersensitivity angiitis, allergic granulomatous angiitis, rheumatic angiitis, 
temporal arteritis. It was based on pathological data and damage and on their sizes. On the 
basis of etiologic and pathogenetic, clinical and pathomorphological criteria has been done 
many classifications of SV. But they are all flawed, because there are several factors that may 
affect the objectivity of classification opinions. They include: location and technology 
collection of fabrics, including various vascular pools, the possibility of angiography, 
variability in cellular composition depending on the morphogram stage, previous treatment 
options etc.  
Primary systemic vasculitis has an incidence of more than 100 new cases per million. 
Currently, the most widely adopted vasculitis classification system is that of Chapel Hill 
Consensus Conference (CHCC), which is based on pathological criteria. The other widely 
used system is that of the American College of Rheumatology (ACR), which is based 
predominately on clinical findings. 
The etiology of the systemic vasculitis is largely unknown, although they are widely believed 
to be autoimmune in origin, triggered by different environmental events.  Epidemiologic 
studies have indicated factors, including silica exposure, infection, seasonal variation in 
occurrence, drugs, ultraviolet radiation and vitamin D, latitudinal gradient and etc. 
Pathogenic mechanisms remain uncertain. In the modern literature widely discusses the 
pathogenic role in the development of systemic vasculitis of neutrophils, eosinophils, 
antineutrophil cytoplasmic antibodies, circulating immune complexes, lymphocytes, 
cytokines, total IgE and etc. 
In general, systemic symptoms accompany all cutaneous vasculitic syndromes, and these 
symptoms include fever, malaise, weight loss, arthritis and ⁄ or arthralgias. In the majority of 
patients, vasculitic lesions will affect the lower extremities, mostly at dependent sites or 
underlying tight-fitting clothes. Upper extremity, trunk and head and neck involvement are 
infrequent and often signal the presence of more severe disease or coexisting systemic 
vasculitis.  The subtlety and diversity of symptoms in the initial phase of vasculitis can be a 
real diagnostic problem, and thus early recognition of a vasculitic condition relies on the 
experience of a team of dedicated professionals from several different subspecialties, 
including laboratory medicine. The initial assessment will be to make a diagnosis, categorize 
disease severity and formulate a management plan. A structured approach, based on careful 
disease staging and evaluation, is the cornerstone of good disease management. Initial 
evaluation includes a comprehensive clinical assessment, serological tests, radiology and 
histology. The first step in the patients management is clinical history and examination, the 
second one of the initial investigations include full blood count, inflammatory markers [C-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR)], renal function such as 
epidermal growth factor receptor (eGFR) and serology to include antiglomerular basement 
membrane antibodies. Inflammatory markers provide a non-specific tool for assessing 
inflammatory activity and monitoring treatment. Urinalysis detects proteinuria and 
haematuria.  
Specific diadnostic is based on detection of specific markers: characteristic autoantibodies 
are formed towards enzymes and bactericidal proteins within the cytoplasmic granules of 
neutrophils and monocytes in a substantial proportion of patients with systemic vasculitis 
manifesting as Wegener’s granulomatosis, microscopic polyangiitis and Churg–Strauss 
syndrome, as well as in patients with limited forms of these conditions. Histological 
examination of biopsy material is useful in confirming a diagnosis in the context of clinical 
findings and laboratory data. Also, skin biopsy is the gold standard for the diagnosis of 
www.intechopen.com
 
Churg-Strauss Syndrome: Clinical and Immunological Features 
 
257 
vasculitis type. For subsequent evaluations, it is effective and practical to measure clinical 
disease status for most patients with small and medium vessel vasculitis. Therapy is based 
on the pattern of vasculitis and on careful evaluation of the extent and activity of disease. 
The treatment of vasculitis comprises induction of remission followed by maintenance. 
Remission should be induced rapidly, balancing potential target organ damage against drug 
toxicity. Maintenance with immunosuppression should limit the amount of corticosteroid 
use and prevent relapse. Concomitant medication is used to treat or prevent adverse events 
from immunosuppressive treatment.  
2. Connection between systemic vasculitis, bronchial asthma, eosinophilic 
syndrome and churg-strauss syndrome  
The unreleased question of eiosinophilic background in patients with systemic vasculitis 
and its influence on the disease activity, is very actual today. The most important 
eosinophilic-associated systemic vasculitis between all vascular processes is Churg-Strauss 
syndrome, that occur with eosinophilia asdiagnostic criterion due to ACR,1990. Since its first 
description as allergic granulomatous angiitis in 1951 (Churg and Strauss, 1951), and 
subsequently its affiliation with the small-sized vessel systemic necrotizing vasculitides and, 
more specifically, the so-called subgroup of antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitides in the early 1990s, knowledge about the pathophysiological 
mechanisms of Churg-Strauss syndrome has greatly improved. Its natural clinical history 
and progression are better understood, but the syndrome’s potential subsets are not yet 
totally elucidated. Major advances have also been made in the therapeutic management of 
affected patients, but much remains to be done because sustained off-treatment remissions 
are quite rare and patients often require a long-term low-dose corticosteroid therapy (Cohen 
et al., 2007; Ribi et al., 2008). International studies and workshops on vasculitis classification, 
immunology, genetics, and treatments are ongoing or planned. Here, we review the current 
known aspects of Churg-Strauss syndrome (Pagnoux, 2010).  Churg-Strauss syndrome is a 
rare disease, with an annual incidence ranging between 0.5 and 6.8 per million inhabitants 
and a prevalence of 10.7-14 per million inhabitants (Pagnoux et al., 2007; Watts et al., 2005), 
with a mean age at onset around 50 years and no sex preponderance. No strong evidence of 
a differential geographical distribution pattern has been reported so far, nor a blatant 
change in its frequency over the past decades. However, some studies reported a slightly 
higher prevalence in northern, as opposed to southern, Europe, and in urban, as compared 
to rural, regions. 
Several exogenous triggering factors for disease onset or flares have been identified or, more 
cautiously, suspected in some European or North American studies. They include 
vaccinations, desensitizations, and drugs, such as macrolides, carbamazepine, quinine, and 
also anti-asthma agents, like leukotriene-receptor antagonists and, more recently, 
omalizumab, a recombinant monoclonal anti-immunoglobulin E (IgE) antibody (Bibby et al., 
2010; Pagnoux et al., 2007). These latter two often provide the opportunity for substantial 
tapering or withdrawal of corticosteroids in asthmatic patients, thereby unmasking an 
underlying ‘forme fruste’ of Churg-Strauss syndrome, which had so far been controlled by 
corticosteroids, but a direct triggering role of these agents cannot be excluded (Bibby et al., 
2010). Whether or not “common” asthma represents a risk factor for Churg-Strauss 
syndrome per se has not been clearly determined, because both conditions share some 
underlying mechanisms. The earliest studies reported a higher annual incidence of Churg-
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Strauss syndrome in asthmatic patients treated with non-leukotriene-modifying asthma 
drugs (64.4 per million asthmatics) or a leukotriene-receptor antagonist (about 60 per 
million asthmatics). A more recent study reported a somewhat lower Churg-Strauss 
syndrome incidence of 34.6 per million asthmatics per year (Harrold et al., 2005), which 
remains higher than in the general population; but other reported incidences varied from 0 
to 67 according to disease definition. Whereas asthma often clusters in families, familial 
cases of Churg-Strauss syndrome are exceptional, diminishing the gene and environmental 
factor impact on the latter. However, results of several genetic studies suggested some 
predisposing hereditary factors, like the HLA-DRB1*04 and HLA-DRB1*07 alleles and the 
HLA-DRB4 gene, which are more frequent in Churg-Strauss syndrome patients than healthy 
controls, the interleukin IL10.2 haplotype, which is associated with enhanced IL-10 
expression, and possibly the CD226 Gly307Ser polymorphism (Wieczorek et al., 2010).  
Its most typical presentation consists of the appearance, in a patient with late-onset asthma, 
of vasculitic manifestations, like fever, cutaneous purpura and mononeuritis multiplex. In 
such a setting, the combination of blood eosinophilia and inflammatory syndrome is highly 
suggestive of the diagnosis, which can be further supported by the detection of 
antineutrophil cytoplasmic antibodies (ANCA), especially P-ANCA (perinuclear-ANCA) 
with anti-myeloperoxidase specificity and the presence of eosinophilic granulomas and/or 
necrotizing vasculitis in an affected-tissue biopsy. Asthma is the most common sign of 
Churg-Strauss syndrome, but Churg-Strauss syndrome can cause a variety of problems, 
ranging from hay fever, rash and gastrointestinal bleeding, to severe pain and numbness in 
your hands and feet. The wide range of symptoms — and their similarity to symptoms of 
other disorders — make Churg-Strauss syndrome challenging to diagnose. Biological 
phenotypes of interest for assessing severity of Churg-Strauss syndrome may be IgE level, 
ANCA,  cytokines (IL-2, 4, 5, 10) and eosinophilia. Phenotypes other than usual Churg-
Strauss syndrome need to be considered. Phenotypic heterogeneity may help to disentangle 
etiologic heterogeneity. Churg-Strauss syndrome, its verification and activity could be 
mediated by different pathogenetic mechanisms and realized mediators, such as ANCA, 
eosinophils, cytokines, total  IgE etc. Severity of eosinophilia in patients with Churg-Strauss 
syndrome represents a clinical subphenotype of interest, and studying severe eosinophilia 
(extreme phenotype) may increase the power to detect linkage. It would be useful to define 
Churg-Strauss syndrome phenotypes unencumbered by the activity of disease, which may 
depend heavily on nongenetic factors, and free of gene-trigger interactions. Besides the 
activity, environmental factors and inadequate treatment can modify the severity of the 
Churg-Strauss syndrome phenotype. Consideration of treatment as a marker of severity 
implies that the relevant phenotype for etiological research is masked by the treatment. 
Intermediate Phenotypes  
Intermediate phenotypes are important with respect to pleiotropy and etiological 
heterogeneity. Bronchial hyperresponsiveness, total IgE, eosinophilia, ANCA-presence and 
vacular involvement  are usually considered intermediate phenotypes for Churg-Strauss 
syndrome.   
Refinement of Phenotypes 
Considering environmental factors and potential interactions with genetic factors may 
increase our ability to detect genetic factors in multifactorial diseases such as Churg-Strauss 
syndrome.  
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There is increasing evidence that the associations of ANCAs, total IgE, and eosinophilia with 
environmental and clinical factors are different in patients with Churg-Strauss syndrome 
and different eosinophilia severity. 
The most typical clinical presentation of Churg-Strauss syndrome is the appearance of 
vasculitic manifestations in a patient with known allergic rhinitis, nasal and sinus polyposis, 
and late-onset asthma (almost constant, and usually preexisting for 5-10 years). General 
symptoms (i.e., fever or weight loss), mononeuritis multiplex, and/or necrotic cutaneous 
purpura are the most frequent manifestations at disease onset, in combination with elevated 
blood eosinophilia and inflammatory syndrome. The detection of ANCA, especially P-
ANCA (with perinuclear labeling pattern in indirect immunofluorescence) with anti-
myeloperoxidase (antiMPO) specificity (in enzyme-linked immunosorbent assay), strongly 
supports the diagnosis, but they are present in only 35-40% of the patients (Sablé-Fourtassou 
et al., 2005; Sinico &Bottero, 2009). While Lanham et al. (1984) commendably described in 
the 1980s that Churg-Strauss disease most typically emerges through 3 successive phases 
(prodromic phase, with asthma and allergic manifestations; then, eosinophil infiltration into 
tissues, especially lung and/or myocardium; and eventually, systemic and vasculitic phase), 
not all patients experience this clear-cut stepwise progression and many have overlapping 
manifestations from these different phases.  
In addition to almost constant asthma and airflow obstruction, lung manifestations include 
patchy and transient alveolar (eosinophilic) infiltrates and/or pleurisy, and, rarely, lung 
non-excavated nodules or alveolar hemorrhage. Allergic rhinitis, sinusitis, and/or nasal 
polyposis can be observed in 60-80% of the patients. Notably, Churg-Strauss syndrome 
patients must be evaluated for heart involvement, because it carries a poor prognosis, has 
therapeutic implications, and can be paucisymptomatic. In the earliest studies, heart 
involvement was reportedly occurring in up to 50-60% of the patients (Pagnoux, 2010) and 
represented the major cause of mortality, accounting for 48% of patient deaths (Pagnoux, 
2010). In more recent reports, outcomes were better. For instance, Neumann et al. (2009) 
reported that there were “only” two deaths from severe endomyocarditis among the 22 
patients with cardiac involvement, with recovery of nearly normal cardiac function in 
almost all of the survivors. 
However, the reported cardiac manifestations and their frequencies are strongly dependent 
on which cardiac investigations were done. Cardiac magnetic resonance imaging might 
reveal clinically silent and echographically undisclosed myocardial involvement, whose 
clinical significance is uncertain today (Bhagirath et al., 2009; Neumann et al., 2009). Cardiac 
screening with magnetic resonance imaging can better delineate inflammatory pericardial 
involvement and reveal microvasculitis of the epi- and myocardial vessels, endo- and/or 
myocardial inflammation, and/or less reversible fibrosis. These are supposedly attributable 
to eosinophil infiltration and/or ischemic lesions due to coronary artery vasculitis, which, 
nonetheless, is rare in Churg-Strauss syndrome (Bhagirath et al., 2009). Intraventricular 
thrombi are other, but rare, possible cardiovascular abnormalities, usually also visible on 
echocardiography. Positron-emission tomography has also been used to evaluate cardiac 
involvement, with some interesting results. 
The aim of this study was to analyze clinical, morphological and immunological features in 
patients with Churg-Strauss syndrome in comparison to the patients with bronchial asthma 
and systemic vasculitis with eosinophilia and to study eosinophils influence on vasculitis, 
especially Churg-Strauss, progression and complication. 
The recognition of eosinophils as complex immunomodulatory cells has been increasing in 
recent years. Eosinophils are derived from hematopoietic stem cells that are committed 
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initially to the myeloid and subsequently to the basophil-eosinophil granulocyte lineage 
(Tefferi, 2005). The material in these granules includes cationic proteins major basic protein, 
eosinophilic cationic protein, eosinophil-derived neurotoxin, eosinophil peroxidase), 
cytokines (interleukins [ILs], tumor necrosis factor), and lipid mediators (leukotriene C4) 
(Rothenberg, 1998). Interleukin 5 is considered the major eosinophil growth and survival 
factor, whereas chemokines (eotaxin, platelet-activating factor, RANTES [regulated on 
activation, normal T expressed and secreted]) and endothelial adhesion molecules 
(integrins, vascular cell adhesion molecules) contribute to eosinophil trafficking (Elsner & 
Kapp, 2001; Tefferi, 2005). Major basic protein, eosinophil cationic protein, and eosinophil-
derived neurotoxin are the primary mediators of eosinophil-associated toxicity to microbes 
(parasites, protozoa, bacteria, viruses) and human tissue (myocarditis, pneumonitis, 
dermatitis, neuropathy, vasculitis) (Gleich, 2009). The lung and gastrointestinal systems 
constitute the main residence for eosinophils. Blood eosinophilia (absolute eosinophil count 
[AEC] ≥600 cells/μL) is the usual initial clue for the presence of an eosinophilic disorder. 
The degree of blood eosinophilia, in the absence of active treatment, can be categorized into 
mild (AEC 600-1500 cells/μL), moderate (AEC 1500-5000 cells/μL), or severe (AEC >5000 
cells/μL) (Brito-Babapulle, 2003; Tefferi, 2005). Target organ damage is unusual with mild 
eosinophilia, but its occurrence in association with moderate to severe eosinophilia does not 
appear to depend on the specific cause of eosinophilia. The eosinophil has been perceived as 
a terminal effector cell in allergic airway diseases. However, recent work has shown that this 
multifunctional cell could be more involved in the initial stages of allergic disease 
development than was previously thought, particularly with regard to the ability of the 
eosinophil to modulate T-cell responses. In this review, we discuss recent advances that 
suggest that eosinophils can present antigen to naïve as well as to antigen experienced T 
cells, induce T helper 2 cell development, cytokine production or both, and affect T-cell 
migration to sites of inflammation. These findings are changing the way that eosinophil 
function in disease is perceived, and represent a shift in the dogma of allergic disease 
development (Walsh & August, 2010).  
The pathogenesis of eosinophilia and tissue damage in Churg-Strauss syndrome is yet unclear, 
but an unknown allergen or environmental trigger is thought to provoke fatal consequences in 
pre-sensitized asthma patients. On a cellular level, a strong shift towards a Th2-like response 
with massive T-cell activation is evident (Walsh & August, 2010). In vitro, T-cell lines from 
Churg-Strauss syndrome patients produce significant amounts of IL-4 and -13 (Rothenberg, 
1998). This is underlined by the fact that active CSS patients have usually high serum levels of 
IgE and IgE-containing immune complexes (Gleich, 2009). In tissue biopsies, granulomatous 
vasculitic lesions filled with eosinophils, macrophages and lymphocytes are observed (Elsner 
& Kapp, 2001). Local activation with degranulation of eosinophils and subsequent release of 
granule proteins such as eosinophil-derived neurotoxin (EDN) and major basic protein (MBP) 
is thought to contribute to vasculitic damage.  
However, the molecules specifically contributing to eosinophilia and subsequent 
degranulation in Churg-Strauss syndrome are enigmatic. Recently, animal and human studies 
have revealed the role of a chemokine family (‘eotaxins’) involved in tissue eosinophilia and 
eosinophil maturation in allergic asthma and eosinophilic oesophagitis (EO) (Gleich, 2009). To 
date, three members of the eotaxin family have been described: eotaxin-1 (CCL11), eotaxin-2 
(CCL24) and eotaxin-3 (CCL26). All eotaxins bind to and activate chemokine receptor 3 (CCR3) 
but have little homology and seem to possess different physiological properties. We 
hypothesized that these eotaxins might play a role in eosinophilia in Churg-Strauss syndrome 
and thus compared serum levels of eotaxin-1, -2 and -3 in active and inactive Churg-Strauss 
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syndrome patients with healthy controls (HC). Furthermore, we determined local expression 
of eotaxin-3 at sites of active disease in Churg-Strauss syndrome.  
Skin biopsy is the gold standard for the diagnosis of cutaneous vasculitis, whose 
manifestations include urticaria, infiltrative erythema, petechiae, purpura, purpuric 
papules, haemorrhagic vesicles and bullae, nodules, livedo racemosa, deep (punched out) 
ulcers and digital gangrene. Skin biopsy, extending to subcutis and taken from the earliest, 
most symptomatic, reddish or purpuric lesion is crucial for obtaining a high-yielding 
diagnostic sample. Based on histology, vasculitis can be classified on the size of vessels 
affected and the dominant immune cell mediating the inflammation (e.g. neutrophilic 
granulomatous, lymphocytic, or eosinophilic).  
Disruption of small vessels by inflammatory cells, deposition of fibrin within the lumen and 
⁄ or vessel wall coupled with nuclear debris allows for the confident recognition of small 
vessel, mostly neutrophilic vasculitis (also known as leukocytoclastic vasculitis). 
The main histopathological features in the cutaneous lesions of Churg-Strauss syndrome are 
dermal leukocytoclastic vasculitis with a variable eosinophilic infiltrate and non-vasculitic 
tissue eosinophilia with granuloma formation. This wide histopathological spectrum may 
account for the various skin manifestations of Churg-Strauss syndrome. However, the 
unique histopathological combination of dermal eosinophilic vasculitis and subcutaneous 
granulomatous phlebitis accompanied by bulla formation has not been previously 
described. We report an unusual Churg-Strauss syndrome case showing dermal necrotizing 
eosinophilic vasculitis and granulomatous phlebitis in purpuric lesions coupled with 
subepidermal blistering. The blisters showed dermal granulomatous dermatitis and 
eosinophilia without evidence of vasculitis. Dermal necrotizing eosinophilic vasculitis was 
characterized by fibrinoid alteration of the vessel wall, a prominent perivascular 
eosinophilic infiltrate, a few infiltrating histiocytes along the affected vessel wall, and the 
absence of neutrophilic infiltration. The underlying subcutaneous granulomatous phlebitis 
was characterized by an angiocentric histiocytic infiltrate surrounded by marked 
eosinophilic infiltrate. Deposition of cytotoxic proteins and radicals derived from 
eosinophils in the vessel walls and papillary dermis followed by a secondary 
granulomatous response may account for the unique clinical and histopathological features 
in this case (Gleich, 2009; Pagnoux, 2010). 
3. Results of the research 
We identified 30 unselected consecutive patients in whom Churg-Strauss syndrome (14 men 
and 16 women) aged from 19 to 78 years (40,35 ± 2,99 years) was diagnosed clinically at 
internal medicine departments (nephrology, clinical immunology and rheumatology, 
pulmonology, neurology, and others) in Lviv oblast clinical hospital and immunologicaly – 
at the department of clinical immunology and allegrology of Lviv national medical 
university and at West-Ukrainian medical center of clinical immunology and allergology in 
Ukraine between 2000 and 2010. There were observed 30 patients with bronchial asthma (15 
men and 15 women) aged from 18 to 70 years (31,9 ± 4,4 years) and 19 patients with 
systemic vasculitis with eosinophilia (8 men and 11 women) aged from 19 to 78 years (37,6 ± 
3,8 years) and consulted at the department of clinical immunology and allegrology of Lviv 
national medical university and at West-Ukrainian medical center of clinical immunology 
and allergology in Ukraine between 2000 and 2010. We examined the medical records of all 
these patients. Churg-Strauss syndrome was defined according to the Chapel Hill 
Consensus Conference nomenclature (Rothenberg, 1998). The classification criteria for 
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Churg-Strauss syndrome of the American College of Rheumatology (ACR) (Masi, 1990) as 
well as Lanham's (Hammersmith) criteria (Gleich, 2009) were retrospectively applied to the 
study population. All patients had direct (histologic) or indirect (using surrogate markers) 
evidence of vasculitis (Keogh, 2003). Systemic vasculitis with eosinophilia, bronchial asthma 
(according to Global Initiative for Asthma [GINA] guidelines) and eosinophilic syndrome 
(ES) were diagnosed according to approved medical diagnostic protocols too. 
 
Sign 
Patients with 
BA and 
eosinophilia 
(n = 30) 
Patients with 
SV and 
eosinophilia
(n = 19) 
Patients with 
CSS 
(n = 30) P 1-2 P 1-3 P 2-3 
1 2 3 
Abs. % Abs. % Abs. % 
1 2 3 4 5 6 7 8 9 10 
Disease duration 9,6±2,9 8,3±2,1 7,0±2,3 NS NS NS 
Complicated genetic 
(family) allergic 
anamnesis 
19 63,3 10 52,6 23 76,7 NS 0,05 NS 
Complicated 
ontogenetic allergic 
anamnesis 
30 100 10 52,6 21 70 0,001 0,01 0,01 
Polinosis 11 36,7 - - 14 46,7 - NS - 
Food allergy 4 13,3 - - 6 20 - NS - 
Insect allergy 14 46,7 - - 2 6,7 - 0,001 - 
Drug allergy - - 10 52,6 2 6,7 - - 0,001 
Allergic rhinitis 4 13,3  - 11 36,7 - 0,01 - 
Allergic rhinitis and 
nasal poliposis 
4 13,3  - 10 33,3 - 0,01 - 
Bronchial asthma 30 100 - - 26 86,7 0,001 NS 0,001 
Bronchial asthma and 
nasal poliposis 
- - - - 7 23,3 - 0,001 0,001 
Complicated genetic 
(family) autoimmune 
anamnesis 
- - 5 16,7 7 23,3 - - NS 
Often pulmonary 
infection diseases: 
pharyngitis, laryngitis, 
bronchitis, pneumonia 
over the time of year 
18 60,0 14 46,7 17 56,7 NS NS NS 
Table 1. Main anamnesis features in patients with bronchial asthma with eosinophilia, 
systemic vasculitis with eosinophilia and with Churg-Strauss syndrome  (M±m) 
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Clinical manifestations were usually confirmed by instrumental examinations as 
appropriate and/or tissue biopsy. One or more biopsy specimens from affected tissues were 
obtained when considered necessary by the clinicians. A biopsy specimen was considered 
consistent with a diagnosis of Churg-Strauss syndrome when eosinophilic tissue infiltration 
and/or vasculitis were found. Routine laboratory tests were performed in all cases at the 
time of diagnosis and at followup. The presence of ANCAs, IgE, CIC was determined in all 
patients at the time of diagnosis due to the necessity, using approved methods for each 
detection.  
Statistical analysis. All analyses were performed using Stata statistical software, release 8.2 
(Stata Corporation, College Station, TX). The differences between patients with Churg-
Strauss syndrome and different eosinophilia severity in continuous variables were tested by 
the Mann-Whitney U test and in categorical variables by Fisher's exact test. All reported P 
values are 2-sided. P values less than 0.05 were considered significant. 
In the result of this research it was observed some clinical features in patients with Churg-
Strauss syndrome in the comparison with patients with bronchial asthma and systemic 
vasculitis with eosinophilia. 
In patients with bronchial asthma and systemic vasculitis with eosinophilic syndrome, as 
well as Churg-Strauss syndrome have had a variety of anamnesis data(presented in the 
Table 1), severity of clinical symptoms (presented in the Table 2) and features of the course, 
activity and severity (presented in the Table 3).  
The analysis of anamnesis data in the comparable groups of patients has showed in Table 1, 
which includes the following features as duration of the disease - we examined 30 patients 
with Churg-Strauss syndrome and it was fixed an average of 7,0 ± 2,3 years, and in 30 
patients with bronchial asthma  with eosinophilia - 9,6 ± 2,9 years and in 19 patients with 
systemic vasculitis with eosinophilia - 8,3±2,1 years. 
NS- not significant 
Ontogenetic history of allergy was loaded in 21 (70%) patients with Churg-Strauss 
syndrome, in 47,4% patients with SV with eosinophilia (p0,01) and in 30% patients with 
bronchial asthma with eosinophilia (p0,05). Pollen allergy, which manifested with 
pollinosis was found in 14 (46.7%) patients with Churg-Strauss syndrome,  as compared 
with one (36,7%) patient with bronchial and eosinophilia (p 0,05). Complicated genetic 
autoimmune anamnesis was found in 7 (23,3%) patients with Churg-Strauss syndrome and 
in 5 (16,7%) patients with systemic vasculitis with eosinohilia (P0,05) and was not impeded 
in patients with bronchial asthma and eosinophilia.  
Complicated immunodeficiency anamnesis (six or more respiratory diseases during the 
year) was established in 17 (56,7%) patients with Churg-Strauss syndrome, in  18 (60%) 
patients with bronchial asthma and eosinophilia and in  14 (73.6%) patients with systemic 
vasculitis with eosinophilia. 
NS- not significant 
In the Table 2, low level of productivity cough was recorded in 17 (56,7%) patients with 
Churg-Strauss syndrome and in 16 (53,3%) patients with bronchial asthma with eosinophilia 
(p0,05). Complicated nasal breathing was found in 21 (70%) patients with Churg-Strauss 
syndrome and in 19 (63,3%) patients with bronchial asthma and eosinophilia (p0,05). 
Typical night asthma attacks were noted in 5 (16,7%) patients with bronchial asthma with 
eosinophilia, in 14 (46,7%) patients with Churg-Strauss syndrome (p0,01). Skin itching 
www.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 
 
264 
were found in 17 (56,7%) patients with Churg-Strauss syndrome and in 8 (26,7%) patients 
with bronchial asthma with eosinophilia (p0,05) and in patients with systemic vasculitis 
with eosinophilia (p0,05). Erythematous rash noted in 7 (23,3%) patients with Churg-
Strauss syndrome,  in 4 (21%) patients with systemic vasculitis with eosinophilia (p0,05); 
multiform erythema - in 6 (20%) patients with Churg-Strauss syndrome and in 5 (26,3%) 
patients with systemic vasculitis with eosinophilia (p0,05). These skin manifestations was 
not typical for patients with bronchial asthma. 
 
Sign 
Patients with 
BA and 
eosinophilia 
(n = 30) 
Patients with 
SV and 
eosinophilia
(n = 19) 
Patients with 
CSS 
(n = 30) P 1-2 P 1-3 P 2-3 
1 2 3 
Abs. % Abs. % Abs. % 
1 2 3 4 5 6 7 8 9 10 
Complaints and 
clinical signs 
         
Underproductive 
cough 
16 53,3 - - 17 56,7 - NS - 
Complicated nasal 
breathing 
19 63,3 - _ 21 70 - NS - 
Night attack of 
coughing 
5 16,7 - - 14 46,7 - NS - 
Skin itching 8 26,6 11 31,6 17 56,7 NS 0,05 0,05 
Erythematous rash - - 4 21,1 7 23,3 - - NS 
Erythema multiforme - - 5 26,2 6 20 NS NS 0,001 
Non-palpable spot 
haemorrhagic rush 
 - - - 6 20,0 - - - 
Palpable spot 
haemorrhagic rush 
- - 2 10,5 14 46,7 - - 0,01 
Haemorrhagic rash 
with confluence ability
- - 1 5,3 18 60,0 - - 0,001 
Papular    rash 3 10,0 4 21,1 14 46,7 NS 0,01 NS 
Vesicular rash - - 6 31,6 19 63,3 NS NS 0,01 
Hyperpyrexia - - 8 42,1 17 56,7 - - 0,05 
Arthralgia - - 11 57,9 20 66,7 - - 0,05 
Arthritis - - 4 21,1 17 56,7 - - 0,01 
Myalgia 22 73,3 18 94,7 23 76,7 NS NS NS 
Lymphadenopathy  - - - 8 26,7 - - - 
Diarrhea - - - - 4 13,3 - - - 
Polyneuropathy 
Weakness 
- - - - 14 46,7 - - - 
16 53,3 17 89,5 21 70,0 NS NS NS 
Table 2. Main anamnesis features in patients with bronchial asthma with eosinophilia, 
systemic vasculitis witheosinophilia and with Churg-Strauss syndrome (M±m) 
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Sign 
Patients with 
BA and 
eosinophilia 
(n = 30)
Patients with 
SV and 
eosinophilia
(n = 19)
Patients with 
CSS 
(n = 30) P 1-2 
P 1-3 
 
P 2-3 
 
1 2 3
Abs. % Abs. % Abs. %
1 2 3 4 5 6 7 1 2 3 
Course 
character 
 
exacerbation - - 5 26,3 10 33,3 - - 0,05 
subacute - - 3 15,8 8 26,7 - - NS 
chronical 22 73,4 11 57,9 12 40 0,05 0,01 0,05 
Disease 
activity 
І degree - - 4 21,1 9 30 - - NS 
ІІ degree - - 13 68,4 14 46,7 - - NS 
 ІІІ degree - - 2 10,5 7 23,3 - - 0,05 
Severity 
stage 
mild 8 26,7 4 21,1 3 10 0,05 0,05 NS 
intermittent
/ 
moderate
14 46,7 11 57,9 21 70 NS 0,05 0,05 
severe 8 26,7 4 21,1 6 20 0,05 NS NS 
Table 3. Trends of course, activity and severity of disease in patients with bronchial asthma with 
eosinophilia,, systemic vasculitis with eosinophilia and with Churg-Strauss syndrome  (M±m) 
In the same time, not-palpable hemorrhagic rash, was detected only in 6 (20%) patients with 
Churg-Strauss syndrome (p0,001); palpating hemorrhagic spot rash - in 14 (46,7%) patients 
with Churg-Strauss syndrome, in 2 ( 10,5%) patients with systemic vasculitis with 
eosinophilia (p0,01); hemorrhagic rash with a penchant of mergers - in 18 (60%) patients 
with Churg-Strauss syndrome, and only in one (5.3%) patient with systemic vasculitis with 
eosinophilia (p0,001). Hemorrhagic eruption of different nature in patients with bronchial 
asthma and eosinophilia were not detected. Papular and vesicular rash were typical for 
patients with Churg-Strauss syndrome too. The common symptoms in examinated patients 
were distributed as follows: hyperthermia was found in 17 (56,7%) patients with Churg-
Strauss syndrome and in 8 (42,1%) patients with systemic vasculitis and eosinophilia 
(p0,05), arthralgic syndrome - in 20 (66,7%) patients with Churg-Strauss syndrome and in 
11 (57,9%) patients with systemic vasculitis and eosinophoilia (p0,05), arthritic syndrome - 
in 17 (56,7%) patients with Churg-Strauss syndrome and in four ( 21,1%) patients with 
systemic vasculitis and eosnophilia (p0,01), mialgia - in 23 (76.7%) patients with Churg-
Strauss syndrome, in 18 (94,7%) patients with systemic vasculitis (p0,05) and in 22 (73,3%) 
patients with bronchial asthma and eosinophilia (p0,05). Importantly, the 
lymphadenopathy was referred only in 8 (26,7%) patients with Churg-Strauss syndrome 
(p0,001), diarrhea - in four (13.3%) patients with Churg-Strauss syndrome (p0,001), 
polyneuropathy - in 14 (46 7%) patients with Churg-Strauss syndrome (p0,001). These 
clinical signs were not identified in other groups of examined patients.  
Weakness was recorded in 21 (70%) patients with Churg-Strauss syndrome and in 17 
(89,7%) patients with systemic vasculitis with easinophilia (p0,05) and  in 16 (53,3%) 
patients with bronchial asthma and eosinophilia (p0,05). 
The most severe and active course of disease is more typical for patients with Churg-Strauss 
syndrome (p0,05), that is presented in the Table 3. 
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Sign 
Patients with 
CSS and mild 
eosinophilia 
(AEC 
600-1500 
cells/μL) 
(n=12) 
Patients with CSS 
and moderate  
eosinophilia (AEC 
1500-5000 cells/μL) 
(n = 13) 
Patients with CSS 
and severe 
eosinophilia (AEC 
>5000 cells/μL) 
(n = 5) 
1 2 3 
Abs. % Abs. % Abs. % 
1 2 3 4 5 6 7 
Polinosis 4 33,3 7 53,8 3 60,0 
Allergic rhinitis 5 41,7 12 92,3 4 80,0 
Allergic rhinitis and nasal 
poliposis 
2 16,7 6 46,2 3 60,0 
Bronchial asthma 9 75,0 12 92,3 5 100 
Nasal poliposis       
Bronchial asthma and 
nasal poliposis 
2 16,7 3 23,1 2 40,0 
Underproductive cough 2 16,7 10 76,9 5 100 
Complicated nasal 
breathing 
4 33,3 12 92,3 5 100 
Bronchial hyperreactivity 3 25,0 11 84,6 3 60,0 
Skin itching 3 25 12 92,3 4 80,0 
Erythematous rash - - 4 30,8 3 60,0 
Erythema multiforme - - 3 23,1 3 60,0 
Non-palpable spot 
haemorrhagic rush 
4 33,3 2 15,4 - - 
Palpable spot 
haemorrhagic rush 
6 50,0 4 30,8 4 80,0 
haemorrhagic rash with 
confluence ability 
2 16,7 11 84,6 5 100,0 
Papular    rash 8 66,7 5 38,5 1 20,0 
Vesicular rash 3 25 12 92,3 4 80,0 
Hyperpyrexia 6 50,0 7 53,8 4 80,0 
Arthralgia 6 50,0 11 84,6 3 60,0 
Arthritis 4 33,3 8 61,5 5 100,0 
Myalgia 6 50,0 12 92,3 5 100,0 
Lymphadenopathy 1 8,3 4 30,8 3 60,0 
Diarrhea 1 8,3 1 8,3 2 40,0 
Polyneuropathy 5 41,7 5 38,5 4 80,0 
Weakness 4 33,3 13 92,3 4 80,0 
Table 4. Main clinical signs in patients with Churg-Strauss syndrome depending of 
eosinophilia severity (M±m) 
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NS- not significant 
There were found some clinical features, which were more typical for patients with Churg-
Strauss syndrome and were more expressed in patients with Churg-Strauss syndrome: 
chronical disease course, ІІІ activity degree and moderate stage of severity are more typical 
for patients with Churg-Strauss syndrome compared with patients with bronchial asthma 
and systemic vasculitis with eosinophilia. 
There were found some clinical signs in patients with Churg-Strausss syndrome depending 
of eosinophilia severity too, that is presented in the Table 4. 
NS- not significant 
For patients with Churg-Strauss syndrome and severe eosinophilia are more typical in 
anamnesis such signs as polinosis, allergic rhinitis, allergic rhinitis with nasal poliposis, 
bronchial asthma with nasal poliposis.  Between clinical signs more typical for patients with 
severe eosinophilia are underproductive, complicated nasal breathing cough, erythematous 
rash, erythema multiforme, palpable spot haemorrhagic rush and  haemorrhagic rash with 
confluence ability, hyperpyrexia, arthritis, lymphadenopathy, diarrhea and polyneuropathy. 
There are many immunological peculiarities that play very important role in the 
opportunity of examined diseases development, activity, severity and complication. Some of 
such immunological peculiarities are presented in the Table 5. 
 
Indexes 
Patients with 
BA and 
eosinophilia
(n = 30)
Patients with 
SV and 
eosinophilia 
(n = 19)
Patients 
with CSS
(n = 30) Р1-2 Р1-3 Р2-3 
1 2 3
Lymphocytes cells/μL) 1,70±0,23 1,86±0,19 1,89±0,12 NS NS NS 
 
CD3+ 
% 63,7±3,18 50,8±2,55 50,8±2,89 0,05 0,05 NS 
cells/μL) 1,08±0,12 1,11±0,27 0,96±0,13 NS NS NS 
 
CD4+ 
% 40,9±1,60 29,8±1,75 42,6±2,60 0,05 NS 0,05 
cells/μL) 0,43±0,04 0,31±0,03 0,41±0,10 0,05 NS 0,05 
 
CD8+ 
% 23,3±1,72 21,0±1,67 18,3±1,49 NS NS NS 
cells/μL)
 
0,24±0,03 0,24±0,09 0,18±0,04 NS NS NS 
 
CD16+/56+ 
% 14,1±1,26 16,00±2,59 16,01±1,30 NS NS NS 
cells/μL) 0,25±0,05 0,30±0,07 0,30±0,05 NS NS NS 
 
CD19+ 
% 16,9±1,94 20,8±3,60 22,40±2,24 NS 0,05 NS 
cells/μL) 0,31±0,03 0,38±0,05 0,44±0,07 NS 0,05 NS 
 
CD25+ 
% 17,9±1,12 21,3±1,62 29,4±1,19 NS 0,01 0,05 
cells/μL) 0,34±0,02 0,40±0,05 0,56±0,05 NS 0,001 0,01 
HLA DR+ 
% 27,3±1,22 30,0±1,48 26,30±1,83 NS NS NS 
cells/μL) 0,48±0,02 0,53±0,02 0,50±0,07 NS NS NS 
 
CD95+ 
% 17,3±0,88 18,6±2,66 24,7±1,37 NS 0,05 0,05 
cells/μL) 0,29±0,05 0,35±0,03 0,47±0,05 NS 0,01 0,05 
Table 5. Trends of lymphograme indexes and lymphocytes activity markers in patients with 
bronchial asthma, systemic vasculitis with eosinophilia and with Churg-Strauss syndrome  
(M±m) 
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NS- not significant 
There were found some peculiarities of immunological parameters in patients with Churg-
Strauss syndrome, such as significantly lower proportional level of CD3 +lymphocytes 
(p0,05), higher proportional and absolute level of CD19 +-lymphocytes (p0,05), 
intensively expressed proportional (p0,01) and absolute (p0,001) early  count of 
lymphocyte activation marker (CD25 +)  and significantly intensively proportional (p0,05) 
and absolute (p0,01) expression of CD95+ in patients with Churg-Struss syndrome 
compared with patients with bronchial asthma and eosinophilia. Compared with patients 
with systemic vasculitis with eosinophilia, patients with Churg-Strauss syndrome had a 
significantly higher proportional (p0,05) and absolute (p0,05) mean of CD4 +lymphocytes, 
intensively expressed proportional (p0,05) and absolute (p0,01) count of early lymphocyte 
activation marker (CD25 +)  and significantly intensively proportional and absolute 
expression of CD95+ (p0,05). 
There were found some immunological signs in patients with Churg-Strausss syndrome 
depending of eosinophilia severity too, that is presented in the Table 6. 
 
Indexes 
Patients 
with CSS 
and mild 
eosinophilia 
(AEC 
600-1500 
cells/μL) 
(n=12)
Patients with 
CSS and 
moderate  
eosinophilia 
(AEC 1500-
5000 cells/μL)
(n = 13) 
Patients with 
CSS and 
severe 
eosinophilia 
(AEC >5000 
cells/μL) 
(n = 5) 
Р 1-2 Р 1-3 
Р 2-3 
 
 
 
1 2 3
1 2 3 4 5 6 7 8 
Eosinophils cells/μL) 0,59±0,05 3,58±0,82 5,81±0,92 0,001 0,001 0,05 
Lymphocytes cells/μL) 1,61±0,15 2,24±0,47 3,01±0,15 NS 0,05 NS 
 
CD3+ 
% 56,7±1,66 48,53±2,26 46,50±1,18 0,05 0,05 NS 
cells/μL) 0,91±0,09 1,08±0,05 1,39±0,06 NS 0,05 NS 
 
CD4+ 
% 36,5±2,16 41,20±3,97 50,30±4,21 NS 0,05 0,05 
cells/μL) 0,33±0,06 0,44±0,08 0,70±0,09 NS 0,01 0,01 
 
CD8+ 
% 19,65±1,72 18,50±2,68 16,67±2,33 NS NS NS 
cells/μL) 0,18±0,03 0,20±0,07 0,23±0,07 NS NS NS 
 
CD16+/56+ 
% 14,91±2,07 14,80±1,52 18,3±1,76 NS NS NS 
cells/μL) 0,24±0,03 0,33±0,05 0,55±0,08 NS NS NS 
 
CD19+ 
% 20,05±1,86 22,03±2,61 25,0±2,12 NS 0,05 NS 
cells/μL) 0,32±0,05 0,49±0,03 0,75±0,09 NS 0,05 0,001 
 
CD25+ 
% 28,33±2,73 29,82±1,89 30,4±1,58 NS NS NS 
cells/μL) 0,46±0,07 0,66±0,09 0,92±0,12 NS 0,01 0,05 
 
HLA DR+ 
% 20,05±1,68 26,50±1,46 31,9±2,48 NS 0,05 NS 
cells/μL) 0,32±0,05 0,59±0,06 0,96±0,11 NS 0,001 0,05 
 
CD95+ 
% 20,73±1,27 23,50±2,67 29,9±7,06 NS NS NS 
cells/μL) 0,33±0,03 0,52±0,05 0,89±0,1 NS 0,001 0,05 
Table 6. Trends of lymphograme indexes and lymphocytes activity markers in patients with 
Churg-Strauss syndrome depending of eosinophilia severity (M±m). 
www.intechopen.com
 
Churg-Strauss Syndrome: Clinical and Immunological Features 
 
269 
NS- not significant 
There were found some peculiarities of immunological markers in patients with Churg-
Strauss syndrome and different eosinophilia severity, such as the highest eosinophils level 
in patients with Churg-Strauss syndrome and severe eosinophilia in comparison to the 
patients with mild eosinophilia (p0,001) and moderate eosinophila (p0,05), significantly 
lower absolute level of lymphocytes in patients with Churg-Strauss and severe eosinophilia 
p0,05) in comparison to patients with mild eosinophilia; significantly lower proportional 
and absolute level  of CD3 +lymphocytes (p0,05), CD4 +lymphocytes (p0,05),   CD19 
+lymphocytes (p0,05),  significantly intensively expressed early lymphocyte activation 
markers such as (CD25 +) (p0,01), late lymphocyte activation markers such as (HLA DR +) 
(p0,001) and significantly intensively expression of CD95+ (p0,001) in patients with 
Churg-Struss syndrome and severe eosinophilia compared with patients with Churg-
Strauss syndrome and mild eosinophilia. There were found some significantly lower 
proportional  and absolute level  of CD4 +lymphocytes (p0,05),  absolute level  of CD19 
+lymphocytes (p0,001),  significantly intensively expressed early lymphocyte activation 
markers such as (CD25 +) (p0,05), late lymphocyte activation markers such as (HLA DR +) 
(p0,05) and significantly intensively expression of CD95+ (p0,05) in patients with Churg-
Struss syndrome and severe eosinophilia compared with patients with Churg-Strauss 
syndrome and moderate eosinophilia.  
No significant peculiarities were found in patients with Churg-Strauss syndrome and mild 
or moderate eosinophilia.  
We have also analyzed the features of serum interleukins (IL-2, IL-4, IL-5, IL-10) in patients 
with Churg-Strauss syndrome and other examined groups, that is showed in the Table 7.  
 
Interleukins 
Patients 
with BA 
and 
eosinophilia
(n = 30)
Patients 
with SV and 
eosinophilia
(n = 19) 
Patients 
with CSS 
(n = 30) Р1-2 Р1-3 Р2-3 
1 2 3
IL-2 pg/ml 3,79±0,98 6,31±0,75 8,78±0,26 0,05 0,05 0,01 
IL-4 pg/ml 8,17±0,17 5,38±0,55 6,64±0,16 0,01 0,05 NS 
IL-5 pg/ml 6,60±1,26 12,4±2,28 97,9±17,5 0,001 0,001 0,001 
IL-10 pg/ml 2,88±0,19 3,27±0,29 2,12±0,14 NS 0,05 0,05 
Table 7. Trends of pro-inflammatory (IL-2) and anti-inflammatory (IL-4, IL-5, IL-10) 
cytokines in patients with bronchial asthma, systemic vasculitis with eosinophilia and with 
Churg-Strauss syndrome  (M±m) 
NS- not significant 
Comparing realizing possibility of pro- and anti-inflammatory mechanisms of cytokines 
such as IL-2, IL-4, IL-5 and IL-10 in patients with bronchial asthma with eosinophilia, 
systemic vasculitis with eosinophilia and Churg-Strauss syndrome it was found significant 
increase of IL-4 (p0,01) and IL-5 (p0,001)  level in patients with bronchial asthma and 
eosinophilia, increase of IL-2 (p0,05), IL-4 (p0,05) and IL-5 (p0,05)  in patients with 
systemic vasculitis with eosinophilia, increase of IL-2 (p0,05) and IL-5 (p0,001) level and 
decrease of IL-10 (p0,05) level in patients with Churg-Strauss syndrome. 
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There were found some cytokines production peculiarities in patients with Churg-Strausss 
syndrome depending of eosinophilia severity, that is presented in the Table 8. 
 
Interleukins 
Patients 
with CSS 
and mild 
eosinophilia 
(AEC 
600-1500 
cells/μL) 
(n=12) 
Patients with 
CSS and 
moderate  
eosinophilia 
(AEC 1500-
5000 cells/μL)
(n = 13) 
Patients with 
CSS and 
severe 
eosinophilia 
(AEC >5000 
cells/μL) 
(n = 5) 
Р1-2 Р1-3 Р2-3 
1 2 3 
IL-2 pg/ml 8,44±0,11 8,74±0,16 9,18±0,08 NS 0,05 NS 
IL-4 pg/ml 5,7±0,13 6,8±0,11 7,42±0,09 NS 0,05 NS 
IL-5 pg/ml 32,7±7,5 49,4±9,6 211,6±29,5 NS 0,001 0,001 
IL-10 pg/ml 2,34±0,08 2,04±0,09 1,98±0,05 NS 0,05 NS 
Table 8. Trends of pro-inflammatory (IL-2) and anti-inflammatory (IL-4, IL-5, IL-10) 
cytokines in patients with Churg-Strauss syndrome depending of eosinophilia severity 
(M±m) 
NS- not significant 
Analizing realizing possibility of pro- and anti-inflammatory cytokines such as IL-2, IL-4, IL-
5 and IL-10 in patients with Churg-Strauss syndrome and different eosinophilia severity, it 
was fixed significant increase of IL-2 (9,18±0,08 pg/ml, p0,05), IL-4 (7,42±0,09 pg/ml, 
p0,05), and IL-5 (211,6±29,5 pg/ml, p0,001) and decrease of IL-10 (1,98±0,05 pg/ml, 
p0,05) level in patients with Churg-Strauss syndrome with severe eosinopilia compared 
with patients with Churg-Strauss syndrome and mild eosinophilia. Also, it was fixed 
significant higher IL-5 level in patients with Churg-Strauss syndrome and severe 
eosinophilia compared with patients with moderate eosnophilia (p0,001) too. 
The patients with systemic vasculitis and eosinophilia and with Churg-Strauss syndrome 
were divided in some subgroups depended on ANCA –presence.  
In our series of patients, we found that ANCA positivity was correlated with renal 
involvement, especially with the histologic picture of necrotizing crescentic 
glomerulonephritis, and, to a lesser extent, with constitutional symptoms. Moreover, 
ANCA-positive patients had a significantly higher frequency of certain organ system clinical 
manifestations, such as pulmonary hemorrhage, purpura, and mononeuritis multiplex. In 
contrast, ANCA-negative patients had a higher frequency of heart and (less severe) lung 
disease. 
Limited data have been reported on the correlation between ANCA positivity and the 
clinical features in CSS, even though it should be noted that most (if not all) reported cases 
of necrotizing crescentic glomerulonephritis in CSS involved ANCA-positive (usually MPO 
pANCA) patients, as in our cohort. Moreover, the results of studies of small series of 
patients have suggested that MPO ANCAs may be associated with the onset of glomerular 
disorder in CSS. 
There were fixed some morphological peculiarities in patients with Churg-Strausss 
syndrome depending of eosinophilia severity, that is presented in pictures 1,2 and 3. 
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We have selected the three most informative results of skin-muscular samples biopsies 
patients with Churg-Strauss syndrome with different eosinophilia severity, that reflected in 
three figures. 
 
 
Fig. 1. Churg-Strauss syndrome: Tissue eosinophilia is a frequent finding in cutaneous 
lesions of Churg–Strauss syndrome. Hematoxylin, eosin × 300; clinical: light/mild 
eosinophilia 
 
 
Fig. 2. Churg-Strauss syndrome: Skin biopsy which was indicative of small vessel vasculitis, 
showing the presence of an inflammatory infiltrate predominantly constituted by 
eosinophils and plasmocytes around blood vessels.  Hematoxylin, eosin × 400; clinical: 
medium eosinophilia 
The analysis of the founded morphological features, that were identified in patients with  
Churg-Strauss syndrome with different eosinophilia severity, shoved  eosinophilc 
infiltration of the dermis in patients with Churg-Strauss syndrome and mild eosinophilia 
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(Fig.1); necrotizing changes in the center of granulomas, extensive infiltration of neutrophils, 
eosinophils of vessel wall until the formation of circular eosinophil infiltrates in the vessels 
of patients with Churg-Strauss syndrome and severe eosinophilia (Fig.3) 
 
 
Fig. 3. Churg-Strauss syndrome: Skin-muscular biopsy which showing eosinophilic circular 
infiltration of the intermuscular arteriole. Hematoxylin, eosin × 400; clinical: severe 
eosinophilia 
4. Conclusion  
Substantial advances have been made in the understanding of immune mechanisms 
(especially eosinophils, circulating immune complexes, total IgE, antineutrophicytoplasmic 
antibodies, cytokines) implicated in Churg-Strauss syndrome and its management. While it 
definitively remains a systemic necrotizing small-sized vessel vasculitis, its membership in 
the ANCA-associated vasculitis group has become more controversial. More complex and 
numerous mechanisms are involved in Churg-Strauss syndrome (Hoffman and Langford, 
2005; Pagnoux and Guillevin, 2010). Similarly, one of its earlier denominations, allergic 
granulomatous angiitis (Churg and Strauss, 1951), has become dated because not all patients 
have (eosinophilic) granulomas. Moreover, several disease subgroups have been identified, 
essentially based on clinical or biological findings (Walsh &August, 2010). There are a large 
number of works devoted to studying of the problem of rare disease – Churg-Strauss 
syndrome – especially its clinical and laboratory features, but it was firstly by us described 
clinical, immunological and morphological features of Churg-Strauss syndrome with 
different severity of eosinophilia in these patients.  
It was fixed special clinical signs in patients with Churg-Strauss syndrome and severe 
eosinophilia such as:  underproductive, complicated nasal breathing cough, erythematous 
rash, erythema multiforme, palpable spot haemorrhagic rush and  haemorrhagic rash with 
confluence ability, hyperpyrexia, arthritis, lymphadenopathy, diarrhea and polyneuropathy.  
There were found some peculiarities of immunological markers in patients with Churg-
Strauss syndrome and different eosinophilia severity, such as the highest eosinophils level 
in patients with Churg-Strauss syndrome and severe eosinophilia in comparison to the 
patients with mild eosinophilia (p0,001) and moderate eosinophila (p0,05), significantly 
lower absolute lymphocytes level  in patients with Churg-Strauss and severe eosinophilia 
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(p0,05) in comparison to patients with mild eosinophilia; significantly lower proportional  
and absolute level  of CD3 +lymphocytes (p0,05), CD4 +lymphocytes (p0,05),   CD19 
+lymphocytes (p0,05),  significantly intensively expressed early lymphocyte activation 
markers such as (CD25 +) (p0,01), late lymphocyte activation markers such as (HLA DR +) 
(p0,001) and significantly intensively expression of CD95+ (p0,001) in patients with 
Churg-Struss syndrome and severe eosinophilia compared with patients with Churg-
Strauss syndrome and mild eosinophilia. Other subgroups may be brought forth in the 
future, relying on more subtle molecular and genetic characteristics (IL-4, IL-5, ІL-5RA gene 
polymorphism). 
Therapeutic strategies also require further improvement. Treatment should be adapted as 
closely as possible to each patient’s characteristics. New treatments (monoclonal antibodies) 
are needed to lower the rate of frequent, low-dose but long-term, corticosteroid-dependence 
that represents a major issue and the lingering disappointment in current therapeutic 
strategies for Churg-Strauss syndrome. 
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